▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Acacia Pharma Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.88.
The current consensus among 1 contributing investment analysts is to buy stock in Acacia Pharma Group.
Acacia Pharma Group plc, a hospital pharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, other invasive procedures, or cancer chemotherapy treatments in the United States and internationally. The company's lead product is BAREMSIS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also comprise APD403, an intravenous and oral amisulpride that has completed Phase II clinical trials for the chemotherapy-induced nausea and vomiting treatment; and BYFAVO, an ultra-short-acting and reversible intravenous benzodiazepine sedative/anesthetic, which has completed Phase III clinical trials for the use in invasive medical procedures, such as colonoscopy and bronchoscopy. The company's products are primarily serves anesthesiologists and oncologists. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.